N

NGM Biopharmaceuticals Inc
F:0IK

Watchlist Manager
NGM Biopharmaceuticals Inc
F:0IK
Watchlist
Price: 3.18 EUR -0.31% Market Closed
Market Cap: €265.4m

Net Margin

4.5%
Current
Declining
by 0.1%
vs 3-y average of 4.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.5%
=
Net Income
$9.5m
/
Revenue
$251m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
4.5%
=
Net Income
€9.5m
/
Revenue
$251m

Peer Comparison

Country Company Market Cap Net
Margin
US
NGM Biopharmaceuticals Inc
F:0IK
265.4m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.4B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.8B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
54rd
Based on 15 072 companies
54rd percentile
4.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

NGM Biopharmaceuticals Inc
Glance View

Market Cap
265.4m EUR
Industry
Pharmaceuticals

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

0IK Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
4.5%
=
Net Income
$9.5m
/
Revenue
$251m
What is NGM Biopharmaceuticals Inc's current Net Margin?

The current Net Margin for NGM Biopharmaceuticals Inc is 4.5%, which is below its 3-year median of 4.6%.

How has Net Margin changed over time?

Over the last 7 months, NGM Biopharmaceuticals Inc’s Net Margin has decreased from 4.7% to 4.5%. During this period, it reached a low of 4.4% on Jul 30, 2025 and a high of 4.7% on Dec 1, 2024.

Back to Top